Thus, in order to assess the population of patients who could potentially benefit from single agent or combination therapies using immune checkpoint inhibitors, we profiled a panel of IMT-C related biomarkers (PD-1, PD-L1, CTLA-4 and CD8) and oncogenic biomarkers with relevant targeted therapeutic drugs (EGFR, KRAS, ALK, ROS1 and MET) in NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.